Previous 10 | Next 10 |
home / stock / rcdtf / rcdtf news
Recordati press release ( OTCPK:RCDTF ): 9M GAAP EPS of €1.15. Revenue of €1.38B (+20.0% Y/Y). For further details see: Recordati GAAP EPS of €1.15, revenue of €1.38B
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q2 2022 Results Conference Call July 28, 2022 10:00 AM ET Company Participants Federica De Medici - Investor Relations & Corporate Communications Robert Koremans - Chief Executive Officer Luigi La Cort...
Recordati press release ( OTCPK:RCDTF ): 1H GAAP EPS of €0.72. Revenue of €892.49M (+15.8% Y/Y). For further details see: Recordati GAAP EPS of €0.72, revenue of €892.49M
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q1 2022 Results Conference Call May 10, 2022 10:00 AM ET Company Participants Federica De Medici - Investor Relations & Corporate Communications Robert Koremans - Chief Executive Officer Luigi La Corte - Chief Financial Officer Con...
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q4 2021 Earnings Conference Call February 24, 2022 10:00 AM ET Company Participants Federica De Medici - Investor Relations & Corporate Communications Robert Koremans - Chief Executive Officer Luigi La Corte - Chief Financial Offic...
The following slide deck was published by Recordati Industria Chimica e Farmaceutica S.p.A. in conjunction with their 2021 Q4 earnings call. For further details see: Recordati Industria Chimica e Farmaceutica S.p.A. 2021 Q4 - Results - Earnings Call Presentation
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2021 Earnings Conference Call October 28, 2021 10:00 a.m. ET Company Participants Federica De Medici - Investor Relations and Corporate Communications of Recordati Andrea Recordati - Chief Executive Officer Luigi La Corte - Chief Fi...
The following slide deck was published by Recordati Industria Chimica e Farmaceutica S.p.A. in conjunction with their 2021 Q3 earnings call. For further details see: Recordati Industria Chimica e Farmaceutica S.p.A. 2021 Q3 - Results - Earnings Call Presentation
Recordati (OTCPK:RCDTF): Q3 Adj. EBITDA of €147.43M. Revenue of €385.34M (+15.5% Y/Y) Press Release For further details see: Recordati reports Q3 results
Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...
News, Short Squeeze, Breakout and More Instantly...
Recordati Industria Chim Company Name:
RCDTF Stock Symbol:
OTCMKTS Market:
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
Recordati SpA (RCDTF) is expected to report for Q4 2023